Panacea Biotec is currently trading at Rs. 131.65, up by 4.40 points or 3.46% from its previous closing of Rs. 127.25 on the BSE.
The scrip opened at Rs. 131.50 and has touched a high and low of Rs. 132.00 and Rs. 128.00 respectively. So far 13,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 178.10 on 10-Aug-2015 and a 52 week low of Rs. 83.90 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs. 132.00 and Rs. 110.45 respectively. The current market cap of the company is Rs. 806.37 crore.
The promoters holding in the company stood at 74.65%, while Institutions and Non-Institutions held 0.69% and 24.66% respectively.
Panacea Biotec, the country’s third largest biotechnology company has introduced indigenously developed high quality anti-diabetic drug, TENEPAN (Teneligliptin), for treatment of Type 2 Diabetes Mellitus (T2DM). TENEPAN (Teneligliptin) aims to improve accessibility of this treatment for the benefit of patients at an affordable cost as part of company’s commitment to Government of India’s ‘Make in India’ mission.
Panacea Biotec is the third largest biotechnology company as well as among the top 50 pharmaceutical companies of India. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.
